Research progress of fibroblast growth factor 23 in acute kidney injury

Abstract

Fibroblast growth factor 23 (FGF23) is primarily produced in bones and mainly regulates calcium and phosphorus metabolism. The level of circulating FGF23 increases rapidly in the early stage of acute kidney injury (AKI). Recent studies have shown that FGF23 may serve as a biomarker for the diagnosis and poor prognosis of AKI. The mechanism of increased FGF23 in AKI may include increased production of FGF23, decreased renal clearance of FGF23, and some new regulatory factors, such as inflammation and glycerol 3-phosphate. However, the biological effects of elevated FGF23 in AKI are still unclear. It is also not known whether reducing the level of circulating FGF23 could alleviate AKI or its poor prognosis. Here, we review the pathophysiological mechanism and possible regulation of FGF23 in AKI and discuss the possibility of using FGF23 as a therapeutic target.

تقيم عوامل نمو الخلايا الليفيه-23 والفوسفات في المرضى العراقيين الذين يعانون من ضخامة الأطراف

“…Although surgical excision is the chosen main treatment option, it is not always suitable and, depending on the size, invasiveness, and expertise of the surgeon, only controls the illness in around half of patients 17 .While there are currently many other alternatives for medical therapy, including dopamine agonists, growth hormone (GH) receptor antagonists, somatostatin analogs (SSA), and somatostatin receptor ligands (SRL) 18 . Fibroblast Growth Factors-23 (FGF-23) is a 32 kDa glycoprotein 19 , it is essential for maintaining phosphate balance because of the effects they have on their target organs, such as the kidney and parathyroid gland 20 . The FGF-23 is released into the bloodstream by osteoblasts and osteocytes, where it affects the kidney, parathyroid, heart, bone, and perhaps other organs 21 .…”